Key result
Combined moclobemide and paroxetine overdose linked to fatal serotonin syndrome and cardiac arrest.
Why the study?
Deaths primarily attributed to moclobemide and paroxetine are extremely rare due to their lower toxicity compared to older antidepressants.
Case Report (n=1)
Warns of fatal serotonin syndrome risk in moclobemide-paroxetine overdose; confirms interaction lethality but leaves open prospective validation.
A young man was found shivering and incoherent at home. He was placed in bed and was observed having seizures some time later. About four hours after he was initially found, he suffered a full cardiac arrest. Paramedics found his jaw unusually stiff and were unable to open his mouth in order to intubate him. Resuscitation attempts were unsuccessful. The autopsy findings were unremarkable, but toxicology testing revealed the following: moclobemide (subclavian blood, 18.5 mg/L; liver, 28.5 mg/kg; gastric contents, 77 mg/69 g) and paroxetine (subclavian blood, 1.58 mg/L; liver, 15.3 mg/kg; gastric contents, 0.7 mg/69 g). The cause of death was attributed to the combined toxicity of moclobemide and paroxetine. Deaths attributed primarily to these drugs are extremely rare because both are considerably less toxic than older monoamine oxidase and tricyclic antidepressant drugs. Based on the history of the case and pharmacology of the drugs involved, the most likely mechanism of death was severe "serotonin syndrome" resulting from the overdose.
No takes yet. Share an insight, caveat, or question.
Singer et al. (1997) conducted a case report in Combined toxicity of moclobemide and paroxetine / Serotonin syndrome (n=1). Moclobemide and paroxetine overdose was evaluated on Death. Combined overdose of moclobemide and paroxetine resulted in fatal severe serotonin syndrome and cardiac arrest in a young man.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: